Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

NVCR

Phase 2

Atezolizumab, Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T

Metastatic pancreatic cancer

2026

PANOVA-4 study. Topline data in 2026.

Data Readout

TECX

Phase 1b

TX45

Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

2026

APEX trial. 9/19/24- Topline Ph1a data reported. Ph2 initiated. 11/11/24- Ph1b proof-of-concept trial data in late Q1 or early Q2 2025. APEX Ph2 data in 2026. 1/30/25- Topline data in 2026.

Data readout

SNDX

Phase 2

Axatilimab (SNDX-6352)

Idiopathic pulmonary fibrosis (IPF)

2026

MAXPIRe trial. Initiate trial in YE 2023. 3/25/24- Enrollment ongoing. 1/13/25- Enrollment completion in 2025 w/ topline data in 2026.

Data readout

EYPT

Phase 3

DURAVYU™ (vorolanib intravitreal insert) (EYP-1901)

wAMD (wet Age-related Macular Degeneration)

2026

DAVIO 2, LUGANO, LUCIA trials. 12/04/23- Ph2 topline data announced. 10/24/24- First patient dosed in LUGANO trial. 12/4/24- First patient dosed in LUCIA trial. 3/5/25- Trial completion in H2 2025 w/ topline data in 2026.

Data readout

ANVS

Phase 3

Buntanetap (ANVS401)

AD (Alzheimer's Disease)

H2 2026

4/29/24- Reported Ph2/3 data. 10/15/24- End-of-Ph2 meeting. 2/25- Ph3 trial initiated. 3/21/25- 6mt data readout in H2 2026 and 18mt data in H2 2027.

Data readout

NVCR

Phase 3

Optune Gio® w/ radiation therapy & temozolomide (TMZ)

Glioblastoma (GBM)

2026

TRIDENT trial. 1/9/24 Last patient enrolled. Final data anticipated in 2026. Real-World Data at ESMO 2024 on 9/16.

Data Readout

TEVA

Phase 3

TEV-’248 (ICS/SABA)

Asthma

H2 2026

Collab. w/ Launch Therapeutics. Phase 3 results in H2 2026.

Data readout

AKRO

Phase 3

Efruxifermin (FGF-21 mimetic)

Pre-cirrhotic NASH (Non-alcoholic Steatohepatitis)

2026

SYNCHRONY (Histology & Real World) trials. 12/18/23- First patient dosed. 11/8/24- Report results for primary endpoints in 2026 and the H1 2027.

Data readout

IONS

Phase 3

Bepirovirsen (IONIS-HBVRx)

CHB (Chronic hepatitis B virus)

2026

2/1/23 Initiated Ph3 trial. GSK presented positive data from the Ph2b B-Clear study. Presented data at the AASLD The Liver Meeting®. Ph3 data in 2026.

Data Readout

AVTX

Phase 2

AVTX-009

Hidradenitis suppurativa (HS)

2026

LOTUS trial. 3/27/24- Acquired the asset through AlmataBio acq. 10/8/24- Dosed first patient with topline data in 2026.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20